To design a peptide for SIRT5 knockdown as a potential clinically applicable treatment for ischemic stroke, we synthesized a short peptide (Tat‐SIRT5‐CTM) composed of an 11‐amino acid sequence encompassing the K166 desuccinylation site of ANXA1 and the five upstream and downstream amino acids (amino acids 161 to 171; KRDLAKDITSD), which specifically binds to and then leads to the lysosomal degradation of SIRT5 (Figure 1A). This evidence concerns the gene ANXA1 and ischemic stroke.